June 24, 2020 / 12:03 PM / 10 days ago

BRIEF-Camurus: Results From Phase 2 Study

June 24 (Reuters) - Camurus AB:

* POSITIVE RESULTS FROM PHASE 2 STUDY OF ONCE-WEEKLY FLUIDCRYSTAL® FORMULATION OF SETMELANOTIDE IN HEALTHY VOLUNTEERS WITH OBESITY

* CAMURUS AB - BOTH WEEKLY AND DAILY FORMULATIONS OF SETMELANOTIDE WERE OBSERVED TO BE SAFE AND WELL-TOLERATED

* CAMURUS AB - CAMURUS’ PARTNER RHYTHM PHARMACEUTICALS, INC. TODAY ANNOUNCED INTERIM DATA FROM A PHASE 2 STUDY EVALUATING ONCE-WEEKLY SETMELANOTIDE, CAM4072, AN INVESTIGATIONAL MELANOCORTIN-4 RECEPTOR (MC4R) AGONIST Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below